{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-214706","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2023-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.982845+00:00","generated_at":"2026-06-11T07:39:01.868521+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Selecta posts Q2 net loss of $11.4M; suspends pipeline investment to focus on SEL-212 BLA filing in 1H 2024","bullets":["Net loss of $11.4M ($0.07/share) vs net income of $8.6M ($0.06) in Q2 2022; collaboration revenue fell to $5.2M from $39.3M.","Cash, equivalents, restricted cash, marketable securities $115.0M as of June 30, 2023; expected to fund operations into 2027.","BLA submission for SEL-212 (chronic refractory gout) on track for 1H 2024; eligible for up to $615M in remaining milestone payments from Sobi.","Halting further investment in pipeline assets including ImmTOR-IL; evaluating licensing/corporate development for pipeline programs.","Partnership with Astellas for Xork IgG protease in LOPD continues; Xork designed to expand gene therapy access."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-214706","json":"https://secwatch.observer/filing/0001193125-23-214706.json","markdown":"https://secwatch.observer/filing/0001193125-23-214706.md","text":"https://secwatch.observer/filing/0001193125-23-214706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523214706/0001193125-23-214706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523214706/d541263d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T07:39:01.868521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}